Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha

Cancer Immunology Immunotherapy

Volumn 47, Issue 3, 1998, Pages 157-166

  Tonini, Giuseppe ^a   Nunziata, Corrado ^a,b   Prete, Salvatore P ^a   Pepponi, Rita ^b   Turriziani, Mario ^a   Masci, Giovanna ^a   Graziani, Grazia ^a   Bonmassar, Enzo ^c   De Vecchis, Liana ^a,d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Breast cancer; Chemo immunotherapy; CMF; Interferon alpha

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; FLUOROURACIL; INTERLEUKIN 2; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; LEUKOCYTE COUNT; LEUKOPENIA; NATURAL KILLER CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES; METHOTREXATE; PILOT PROJECTS;

EID: 0031770891     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050516     Document Type: Article

References (58)

1. Adler A, Stein JA, Ben-Efraim S (1980) Immunocompetence. immunosuppression, and human breast cancer I and III. Cancer 45:2061
2. Armant M, Delespesse G, Sarfati M (1995) IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. Immunology 85:331
3. Banks RE, Forbes MA, Hallam S, Jenkins A, Wadhwa M, Dilger P, Meager A, Thorpe R, Bowner CJ, Joffe JK, Patel P, Johnson PWM, Selby PJ (1997) Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines. Br J Cancer 75:1842
4. Benveniste EN, Merril JE (1986) Stimulation of oligodendroglial prolifration and maturation by interleukin-2. Nature 321:61
5. Blomgreen H, Cantell K, Johansson B, Lagergren C, Ringborg U, Strander H (1976) Interferon therapy in Hodgkin's disease. Acta Med Scand 199:527
6. Bolton PM, Teasdale C, Mander AM, James SL, Davidson JM, Whitehead RH, Newcombe RG, Hughes LE (1976) Immune competence in breast cancer: relationship of pretreatment immunologic tests to diagnosis and tumor stage. Cancer Immunol Immunother 1:251
7. Bonmassar E, Cudkowicz G, Vadlamudi S, Goldin A (1970) Influence of tumor-host differences at a single histocompalibility locus(H-1) on the antileukemic effect of 1,3-bis-(2-chloroethyl)-nitrosourea (NSC 409962). Cancer Res 30:2538
8. Came PE, Moore DH (1971) Inhibition of spontaneous mammary carcinoma of mice by treatment with interferon and poly 1: C Proc Soc Exp Biol Med 137:304
9. Chabner BA (1993) Anticancer drugs. In: De Vita VT Jr. Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. Lippincott, Philadelphia, pp 325-417
10. Creekmore SP, Harris JE, Ellis TM, Braun DP, Cohen II, Bhoopalam N (1989) A phase I clinical trial of recombinant interleukin-2 by periodic 24-hours intravenous infusions. J Clin Oncol 7:276
11. Cudkowicz G, Bennett M (1971) Peculiar immunobiology of bone marrow allografts. I. Graft rejection by irradiated "responder" mice. J Exp Med 134:83
12. D'Atri S, Fuggetta MP, Giganti G, Tentori L, Roselli M, Nunziata C, Pastors S, Bonmassar E, De Vecchis L (1988) Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy. Cancer Immunol Immunother 27:163
13. De Filippi R, Cucchiara G, Prete SP, Marini S, Ricci F, Nunziata C, Turriziani M, Bonmassar E, Fuggetta MP, De Vecchis L (1991) Immuno-chemotherapy of advanced colorectal cancer with alpha-2a interferon and 5-fluorouracil. Immunopharmacological studies. Ann Oncol 2:759
14. De Vecchis L, Nunziata C, Ricci F, Cucchiara G, Picconi A, Bonmassar G, Lagomarsino Caprino M, Bonmasser E (1989) Immnochemotherapy of advanced colorectal cancer with α-interferon and 5-fluorouracil. I. Toxicological studies. J Chemother 1:128
15. Eilber FR, Morton DI (1970) Impaired immunological reactivity and recurrence following cancer surgery. Cancer 25:362
16. Ettinghausen SE, Lipford EH III, Mule JJ, Rosenberg SA (1985) Systemic administration of recombinant interleukin-2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol 135:1488
17. Ettinghausen SE, Lipford EH III, Mule JJ, Rosenburg SA (1985) Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine activated killer (LAK) cells. J Immunol 135:3623
18. Fuggetta MP, Aquino A, Pepponi R, D'Atri S, Lanzilli G, Bonmassar E, Graziani G (1993) In vitro combined effects of human interferons and interleukin-2 on natural cell-mediated cytotoxicity. Int J Immunopharmacol 15:1
19. Girard G, Gosselin J, Heitz D, Paquin R, Beaulieu AD (1995) Effects of interleukin-2 on gene expression in human neutrophils. Blood 86:1170
20. Gresser I (1977) On the mechanisms of the antitumor effects of interferon. Tex Rep Biol Med 35:394
21. Gresser I (1985) How does interferon inhibit tumor growth? In: Gresser I (ed) Interferon 6. Academic Press, New York, pp 93-118
22. Gresser I, Maury C, Brouty-Boye D (1972) Mechanism of the antitumor effect of interferon in mice. Nature 239:167
23. Guida M, Abbate I, Casamassima A, Musci MD, Latorre A, Lorusso V, Correale M, De Lena M (1995) Long-term subcutaneous recombinant interleukin-2 as maintenanace therapy: biological effects and clinical implication. Cancer Biother 10:195
24. Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Harsh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S (1980) Leucocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93:399
25. Hancock WW, Muller WA, Cotran RS (1987) Interleukin-2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal human lung macrophages, blood monocytes cell lines. J Immunol 138:185
26. Harrison DE, Carlson GA (1983) Effects of beige mutation and irradiation on natural resistance to marrow grafts. J Immunol 130:484
27. Hengst JCD, Mitchell MS (1980) Principle of combining biological response modifiers with cancer chemotherapy. In:Hellmann K, Carter SK (eds) Fundamentals of cancer chemotherapy. McGraw-Hill, New York, pp 64-76
28. Herberman RB, Ortaldo JR, Bonnard GD (1979) Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 277:221
29. Huschtscha LI, Bartier WA, Ross CE, Tattersall MH (1996) Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer 73:54
30. Idestrom K, Cantell K, Killander D, Nilsson K, Strander H, Willems J (1979) Interferon therapy in multiple myeloma. Acta Med Scand 205:149
31. Iorio AM, Neri M, Enrico P, Goldin A, Bonmassar E (1981) Combined effects of natural resistance and chemotherapy against a murine lymphoma in lethally irradiated mice. Int J Cancer 28:497
32. Karre K, Hans M, Kiessling R (1991) Multiple interactions in the natural killer workshop. Immunol Today 12:343
33. Kodo H, Bonavida B, Colvin M, Gale RP (1985) Dose-response effects of 4-hydroxyperoxycyclo-phosphamide on human T and B cell function in vitro. Int J Immunopharmacol 7:555
34. Lotzova E, Savary CA, Quesada JR, Gutterman JU, Hersh EM (1980) Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon. J Natl Cancer Inst 71:903
35. Lozzio CB, Lozzio BB (1979) Properties and usefulness of the original K562 human myelogenous leukemia cell line. Leuk Res 3:363
36. Malkovsky M, Loveland B, North M, Asherson GL, Gao L, Ward P, Fiers W (1987) Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature 325:262
37. Mellstedt H, Ahre A, Bjorkholm M, Holm G, Johansson B, Strander H (1979) Interferon therapy in myelomatosis. Lancet 1:245
38. Merluzzi VJ, Walker MM, Fananes RB (1981) Inhibition of cytotoxic T-clonal expansion by cyclophosphamide and the recovery of cytotoxic T-lymphocyte precursors by supernatants from mixed lymphocytes cultures. Cancer Res 41:850
39. Mihich E (1969) Combined effects of chemotherapy and immunity against leukemia L1210 in DBA 2 mice. Cancer Res 29:848
40. Park SK, Brody JI, Wallace HA, Blakemore WS (1971) Immunosuppressive effect of surgery. Lancet 1:53
41. Riccardi C, Bartocci A, Puccetti P, Spreafico F, Bonmassar E, Goldin A (1980) Combined effects of antineoplastic agents and anti-lymphoma allograft reactions. Eur J Cancer 16:23
42. Roder JC, Karre K, Kiessling R (1981) Natural killer cells. Prog Allergy 28:66
43. Rook AH, Masur H, Laue HC, Frederick W, Kasahara T, Macher AM, Djeu JY, Manischewitz JF, Jackson L, Fauci AS, Quinnan GV Jr (1983) Interleukin-2 enhances the depressed natural killer and cytomegalovirus specific cytotoxic activities of lymphocytes from patients with the acquired immune deliciency syndrome. J Clin Invest 72:398
44. Rosenberg SA, Lotze MT, Mule JJ (1988) New approaches to the immunotherapy of cancer Ann Intern Med 108:853
45. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the sytemic administration of recombinant interleukin 2. J Immunol 137:1735
46. Rutella S, Sica S, Rumi C, Martucci R, Etuk B, De Stefano V, Testa U, Leone G, Peschle C (1996) Hypereosinophilia during 2-chlorodeoxyadenosine treatment for hairy cell leukaemia. Br J Haematol 92:426
47. Stein RC, Malkovska V, Morgan S, Galazka A, Aniszeski C, Roy SE, Shearer RJ, Marsden RA, Bevan D, Gordon-Smith EC, Coomes RC (1991) The clinical effects of prolonged treatment of patients with advanced cancer with low dose subcutaneous interleukin-2. Br J Cancer 63:275
48. Steiner G, Tschachler E, Tani M, Malek TR, Shevach EM, Holter W, Knapp W, Wolff K, Stingl G (1996) Interleukin 2 receptors on cultured murine epidermal Langerhans cells. J Immunol 137:155
49. Stern JB, Smith KA (1986) Interleukin-2 induction of T cell G1 progression and emyb expression. Science 233:203
50. Stjernsward J (1974) Decreased survival related to irradiation postoperatively in early operable breast cancer. Lancet 11:1285
51. Swain SL (1991) Lymphokines and the immune response: the central role of Interleukin-2. Curr Opin Immunol 3:304
52. Tentori L, Fuggetta MP, D'Atri S, Aquino A, Nunziata C, Roselli M, Ballatore P, Bonmassar E, De Vecchis L (1987) Influence of low-dose beta-interferon on natural killer cells activity in breast cancer patients subjected to chemotherapy Cancer Immunol Immunother 24:86
53. Teutori L, Leonetti C, Lanzilli G, Bonmassar E (1990) IL-2 reverses the inhibition of cytotoxic T-cell responses induced by 5-(3.3′dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vitro. Int J Immunopharmacol 12:831
54. Toivanen A, Nordman E (1981) Long-term effect of postoperative irradiation of the immune functions in patients with mammary carcinoma. Acta Radiol Oncol 20:119
55. Toribio ML, Gutierrez-Ramos JC, Pezzi L, Marcos MAR, Martinez AC (1989) Interleukin-2 dependent autocrine proliferation in T-cell development. Nature 342:82
56. Verdecchia MC, Prete SP, Marcotullio D, Bonmassar E, De Vecchis L (1993) NK cell activity after surgery in head-neck cancer patients. J Exp Clin Cancer Res 12:141
57. Waldmann TA, Goldman CK, Robb RJ, Depper JM, Leonard WJ, Sharrow S (1984) Expression of interleukin-2 receptors on activated human B cells. J Exp Med 160:1450
58. Woefuly G, Brooks N, Riffle B (1996) Effect of rapamycin on the expression of the IL-2 receptor (CD25). Clin Exp Immunol 103:22